Combined modality therapy with TRAIL or agonistic death receptor antibodies.
Molecularly targeted therapies, such as antibodies and small molecule inhibitors have emerged as an important breakthrough in the treatment of many human cancers. One targeted therapy under development is tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) due to its ability to induce apoptosis in a variety of human cancer cell lines and xenografts, while lacking toxicity in most normal cells. TRAIL and apoptosis-inducing agonistic antibodies to the TRAIL death receptors have been the subject of many preclinical and clinical studies in the past decade. However, the sensitivity of individual cancer cell lines of a particular tumor type to these agents varies from highly sensitive to resistant. Various chemotherapy agents have been shown to enhance the apoptosis-inducing capacity of TRAIL receptor-targeted therapies and induce sensitization of TRAIL-resistant cells. This review provides an overview of the mechanisms associated with chemotherapy enhancement of TRAIL receptor-targeted therapies including modulation of the apoptotic (death receptor expression, FLIP, and Bcl-2 or inhibitors of apoptosis (IAP) families) as well as cell signaling (NFκB, Akt, p53) pathways. These mechanisms will be important in establishing effective combinations to pursue clinically and in determining relevant targets for future cancer therapies.
Department of Pharmacology and Toxicology, University of Alabama at Birmingham, USA.
Hope M
HM
Amm
Patsy G
PG
Oliver
Choo Hyung
CH
Lee
Yufeng
Y
Li
Donald J
DJ
Buchsbaum
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000378:metabolism / Q000627:therapeutic use*; D017209:Apoptosis; D003131:Combined Modality Therapy; D006801:Humans; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand / Q000819:agonists* / Q000276:immunology / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000378:metabolism* / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand; D053221:TNF-Related Apoptosis-Inducing Ligand
Cancer Res. 2005 Jun 1;65(11):4799-808
15930300
Int J Mol Med. 2005 Dec;16(6):1125-38
16273296
Clin Invest Med. 2003 Oct;26(5):231-42
14596484
Cancer Res. 2003 Mar 15;63(6):1365-70
12649200
J Biol Chem. 2000 Jul 28;275(30):23319-25
10770955
Mol Cancer Ther. 2007 Apr;6(4):1387-99
17431117
J Exp Med. 1999 Apr 19;189(8):1343-54
10209050
Apoptosis. 2007 Aug;12(8):1533-41
17520194
Cancer Res. 2005 Mar 15;65(6):2344-52
15781649
J Pathol. 2001 May;194(1):15-9
11329136
Nat Cell Biol. 2001 Apr;3(4):409-16
11283615
Clin Cancer Res. 2010 Dec 1;16(23):5734-49
20940278
Cancer Res. 2002 Sep 1;62(17):4929-37
12208743
Clin Cancer Res. 2008 Dec 1;14(23):7733-40
19047100
Cancer Chemother Pharmacol. 2003 Sep;52(3):175-84
12811515
FEBS Lett. 1997 Oct 27;416(3):329-34
9373179
Clin Cancer Res. 2006 Jan 15;12(2):584-90
16428504
Oncogene. 2002 Jan 10;21(2):319-27
11803475
Int J Oncol. 2004 May;24(5):1133-40
15067334
Surgery. 2005 Jul;138(1):71-7
16003319
Curr Med Chem. 2006;13(18):2091-100
16918339
Cancer Res. 2004 May 15;64(10):3517-24
15150106
J Biol Chem. 1998 Jun 5;273(23):14363-7
9603945
J Thorac Cardiovasc Surg. 2006 Dec;132(6):1356-62
17140955
Biochem Biophys Res Commun. 2001 Jan 26;280(3):788-97
11162590
Mol Cell Biol. 2000 Jan;20(1):205-12
10594023
Cancer Res. 2003 Aug 1;63(15):4713-23
12907654
Clin Cancer Res. 2008 Apr 1;14(7):2180-9
18381960
Mol Cancer Ther. 2004 Jun;3(6):699-707
15210856
Blood. 2001 Aug 1;98(3):795-804
11468181
Science. 1997 Aug 8;277(5327):815-8
9242610
Genes Dev. 1999 Feb 1;13(3):239-52
9990849
Cancer Res. 2007 Feb 15;67(4):1430-5
17308080
Oncogene. 2003 Mar 20;22(11):1653-62
12642868
Biochem Biophys Res Commun. 2003 May 9;304(3):437-44
12729577
Apoptosis. 2005 Dec;10(6):1411-8
16215673
J Natl Cancer Inst. 2008 May 7;100(9):649-62
18445820
Cancer Res. 2003 Oct 15;63(20):6815-24
14583479
Oncogene. 2006 Aug 24;25(37):5145-54
16636678
Cancer Res. 2002 Oct 15;62(20):5800-6
12384541
Curr Cancer Drug Targets. 2008 Mar;8(2):132-40
18336196
Apoptosis. 2005 Jan;10(1):35-51
15711921
Cancer Biol Ther. 2005 Jul;4(7):781-6
16082182
Vitam Horm. 2004;67:365-83
15110186
Prostate. 2002 Dec 1;53(4):286-99
12430140
J Biol Chem. 1999 Oct 22;274(43):30603-10
10521444
J Biol Chem. 2000 Aug 18;275(33):25065-8
10862756
J Biol Chem. 1996 May 31;271(22):12687-90
8663110
J Cell Biochem. 2004 Jul 1;92(4):656-63
15211564
Vitam Horm. 2004;67:81-99
15110173
Cancer Res. 2004 May 15;64(10):3607-16
15150119
J Biol Chem. 2001 Sep 14;276(37):34743-52
11461927
Br J Cancer. 2005 Apr 25;92(8):1430-41
15846298
Cell Death Differ. 2004 Aug;11(8):915-23
15118763
Cell Death Differ. 2006 Aug;13(8):1339-50
16763614
Gynecol Oncol. 2006 Apr;101(1):46-54
16271751
J Biol Chem. 2004 Jul 30;279(31):32780-5
15173180
Cancer Res. 2008 Apr 15;68(8):2944-51
18413764
J Biol Chem. 2002 Jun 21;277(25):22320-9
11940602
J Biol Chem. 2005 Jan 21;280(3):2205-12
15520016
Autophagy. 2010 Oct;6(7):891-900
20724831
Clin Cancer Res. 2010 Mar 15;16(6):1701-8
20197482
Nat Cell Biol. 2000 Apr;2(4):241-3
10783243
Vitam Horm. 2004;67:101-32
15110174
Neurobiol Dis. 2009 Feb;33(2):243-9
19027068
Cancer Lett. 2001 Feb 10;163(1):71-81
11163110
Oncogene. 2001 Apr 19;20(17):2122-33
11360196
J Clin Oncol. 2007 Apr 10;25(11):1390-5
17416859
Vitam Horm. 2004;67:1-17
15110168
Leukemia. 2004 Nov;18(11):1780-8
15385934
Immunity. 1997 Dec;7(6):821-30
9430227
J Biol Chem. 2005 Feb 25;280(8):6742-51
15569667
Nat Med. 2007 Sep;13(9):1070-7
17767167
J Clin Invest. 2008 Jun;118(6):1979-90
18523647
Vitam Horm. 2004;67:35-49
15110170
J Thorac Cardiovasc Surg. 2002 Jan;123(1):168-74
11782771
J Clin Invest. 1999 Jul;104(2):155-62
10411544
Science. 1997 Aug 8;277(5327):818-21
9242611
Oncogene. 2002 Aug 22;21(37):5673-83
12173037
Gynecol Oncol. 2007 May;105(2):291-8
17303227
Cancer Lett. 2003 May 8;194(1):107-17
12706864
Future Oncol. 2006 Aug;2(4):493-508
16922616
Eur J Immunol. 2001 Nov;31(11):3138-46
11745330
Leukemia. 2003 Nov;17(11):2122-9
12931220
Autophagy. 2008 Oct;4(7):940-3
18769107
Carcinogenesis. 2004 Oct;25(10):1813-20
15142888
Vitam Horm. 2004;67:275-90
15110182
Oncogene. 2000 Nov 16;19(48):5477-86
11114725
FEBS Lett. 2010 Aug 20;584(16):3519-24
20638385
EMBO J. 1997 Sep 1;16(17):5386-97
9311998
Cancer Res. 1999 Jun 1;59(11):2747-53
10364001
Oncogene. 2010 Aug 26;29(34):4752-65
20531300
Cell Death Differ. 2004 Dec;11 Suppl 2:S193-206
15608694
Science. 1997 Apr 4;276(5309):111-3
9082980
Nat Med. 1999 Feb;5(2):157-63
9930862
J Biol Chem. 2006 Mar 3;281(9):5750-9
16380381
Apoptosis. 2006 Dec;11(12):2251-65
17051334
Prostate. 2004 Sep 15;61(1):35-49
15287092
Vitam Horm. 2004;67:453-83
15110190
Mol Cancer Ther. 2009 Feb;8(2):292-302
19174554
Cancer Res. 2004 May 1;64(9):3006-8
15126334
Clin Cancer Res. 2004 Dec 15;10(24):8284-92
15623604
Apoptosis. 2004 Nov;9(6):667-76
15505410
J Biol Chem. 2009 Apr 24;284(17):11121-33
19261616
Cell Death Differ. 2005 Jul;12(7):773-82
15861184
Mol Cancer Ther. 2004 Jul;3(7):803-12
15252141
Cancer Res. 2001 Feb 1;61(3):1162-70
11221847
Br J Haematol. 2005 Aug;130(4):501-10
16098063
Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1754-9
10677530
Autophagy. 2010 Apr;6(3):322-9
20224296
Oncogene. 2000 Mar 30;19(14):1735-43
10777207
Vitam Horm. 2004;67:51-63
15110171
Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15095-100
14645705
J Immunol. 2008 May 1;180(9):6199-210
18424742
Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3731-41
14506165
J Pathol. 2010 May;221(1):3-12
20225336
Immunity. 1997 Dec;7(6):813-20
9430226
Clin Cancer Res. 2007 Oct 15;13(20):6187-94
17947486
Cancer Res. 2004 Aug 1;64(15):5078-83
15289308
Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3438-43
14993595
Leukemia. 2003 Feb;17(2):379-89
12592338
Ann Oncol. 2008 Jun;19(6):1060-7
18304965
Cancer Res. 2003 Apr 1;63(7):1712-21
12670926
Apoptosis. 2008 Jun;13(6):756-70
18421578
Cell Death Differ. 2008 Apr;15(4):718-29
18202704
Nat Rev Mol Cell Biol. 2005 Apr;6(4):287-97
15803136
Oncogene. 2005 Jan 13;24(3):344-54
15531918
J Biol Chem. 2008 Sep 5;283(36):25003-13
18599488
Vitam Horm. 2004;67:409-26
15110188
Cancer Gene Ther. 2005 Mar;12(3):228-37
15550937
BMC Cancer. 2005 Jan 07;5:2
15638938
Oncogene. 2005 Jun 9;24(25):4052-64
15806163
J Leukoc Biol. 2006 Jan;79(1):123-32
16244105
Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5535s-5543s
17875786
Neuro Oncol. 2010 Jul;12(7):687-700
20511188
Cancer Res. 1999 Feb 1;59(3):734-41
9973225
J Pharmacol Exp Ther. 2001 Oct;299(1):31-8
11561060
Curr Biol. 1997 Dec 1;7(12):1003-6
9382840
Cancer Res. 2002 Jan 15;62(2):488-96
11809700
Proteins. 2008 Feb 1;70(2):333-43
17671978
Cancer Sci. 2003 Dec;94(12):1066-73
14662022
Oncogene. 2002 Apr 4;21(15):2283-94
11948412
Cancer Res. 2007 May 15;67(10):4981-8
17510429
Hepatology. 2000 Sep;32(3):482-90
10960439
Nat Med. 2002 Mar;8(3):274-81
11875499
Curr Opin Cell Biol. 2010 Apr;22(2):246-51
20056398
J Immunol. 1998 Sep 15;161(6):2833-40
9743343
J Biol Chem. 2001 Apr 6;276(14):10767-74
11278284
Cancer Res. 2004 Jul 15;64(14):4900-5
15256461
Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):11003-8
16835297
Lung Cancer. 2008 Jul;61(1):82-90
18255187
Cancer Res. 2003 Mar 1;63(5):1059-66
12615723
Nat Rev Cancer. 2002 Sep;2(9):647-56
12209154
Nat Genet. 1997 Oct;17(2):141-3
9326928
Cancer Biol Ther. 2003 Sep-Oct;2(5):534-40
14614322
Science. 1998 Aug 28;281(5381):1305-8
9721089
Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):507-16
18474311
Oncogene. 2007 Sep 13;26(42):6133-40
17404574
Gynecol Oncol. 2007 May;105(2):481-92
17292950
J Biol Chem. 2001 Dec 7;276(49):46639-46
11583996
Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3198-207
18089714
Oncogene. 2001 Sep 20;20(42):6073-83
11593415
J Biol Chem. 2006 Nov 17;281(46):34742-50
16923815
Cancer Res. 2008 Oct 1;68(19):7956-65
18829553
Int J Cancer. 2003 Apr 20;104(4):409-17
12584736
J Biol Chem. 1998 Jan 30;273(5):2926-30
9446604
J Radiat Res. 2008 Mar;49(2):153-61
18227621
J Biol Chem. 1997 Oct 10;272(41):25417-20
9325248
Arch Ophthalmol. 2005 May;123(5):654-61
15883285
EMBO Rep. 2006 Oct;7(10):988-94
17016456
Int J Cancer. 2005 Oct 10;116(6):860-9
15849742
Cancer Biol Ther. 2005 Oct;4(10):1104-12
16096370
J Mol Med (Berl). 2010 Jul;88(7):729-40
20354842
Hepatology. 2006 Mar;43(3):425-34
16583461
Nitric Oxide. 2009 Feb;20(1):39-52
18778787
J Biol Chem. 2006 Apr 14;281(15):10153-63
16478725
Vitam Horm. 2004;67:189-206
15110178
Immunity. 1995 Dec;3(6):673-82
8777713
Breast Cancer Res. 2009;11(3):R41
19563669
Mol Ther. 2005 Apr;11(4):542-52
15771957
Leukemia. 2004 Oct;18(10):1671-80
15356645
J Biol Chem. 2008 Jul 11;283(28):19665-77
18375389
Hepatology. 2002 Dec;36(6):1498-508
12447876
BMC Cancer. 2005 Jan 14;5:5
15651986
Blood. 2002 Mar 15;99(6):2162-71
11877293
FEBS Lett. 2001 Nov 2;507(3):381-5
11696376
Nat Med. 2000 May;6(5):564-7
10802713
Oncogene. 2004 Oct 28;23(50):8320-32
15467752
J Biol Chem. 1998 Feb 27;273(9):5117-23
9478964
Am J Pathol. 2002 Aug;161(2):643-54
12163389
J Biol Chem. 2007 Apr 27;282(17):12831-41
17327223